The Fund aims to achieve a long-term return, in excess of the long-term return that is typically achieved from United Kingdom equity markets.
Name | % Net Assets |
---|---|
GlaxoSmithKline | 7.1% |
ASTRAZENECA PLC | 5.4% |
BP | 5.2% |
ROYAL DUTCH SHELL | 4.3% |
Vodafone | 3.9% |
HSBC HLDGS | 3.7% |
Unilever | 3.7% |
Centrica | 3.6% |
RSA INSURANCE GROUP PLC | 3.5% |
NATIONAL GRID | 3.4% |
Key | % Net Assets |
---|---|
GlaxoSmithKline | 7.1% |
ASTRAZENECA PLC | 5.4% |
BP | 5.2% |
ROYAL DUTCH SHELL | 4.3% |
Other | 78% |
Date | n/a |
---|---|
Bid | 0.00 |
Offer | 0.00 |
Currency | n/a |
Change | 0.00 |
% | n/a |
YTD change | 0.00 |
YTD % | n/a |
Fund Inception | 01/02/1972 |
---|---|
Fund Manager | Chris Burvill |
TER | 1.66 (30-Nov-2010) |
Minimum Investment | |
---|---|
Initial | 1000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.11 |
You are here: research